KLOW peptide dosage has no established blend score
An exact number can look reassuring. The research doesn’t establish a human dosing plan for all four KLOW ingredients together.

What one human pilot actually used
In Lee and Burgess’s 2025 BPC-157 pilot, researchers gave two adults 10 mg of BPC-157 into a vein on day one and 20 mg on day two. Those are reported study amounts, not a recommendation.
Both participants had received BPC-157 infusions before. The pilot observed short-term safety in two people without a comparison group. It didn’t establish an effective amount for injury recovery. It also didn’t test KLOW, so it can’t explain how to balance four ingredients in a person.
The numbers describe what happened in that experiment. Their precision doesn’t make the evidence any broader. Two people remain too few to establish a dependable safety record.
An animal amount stays an animal amount
The Achilles tendon experiment tested BPC-157 in rats after a deliberately cut tendon. A research amount belongs with that species, injury and route. Adjusting it for body size wouldn’t validate a human KLOW plan.
A human study of full thymosin beta-4 presents a different problem. It tested the larger protein, rather than TB-500. The study’s amounts cannot establish a dose for the smaller fragment or for a mixture containing it.
A study amount only makes sense beside the study that used it. It doesn’t turn an experiment into a personal plan, however precise the number looks.
A ratio is a recipe, not a clinical result
Fixed proportions tell you the relative amounts of ingredients. They don’t tell you whether those ingredients work well together, how their risks combine or which amount has a useful effect. No controlled KLOW study in the evidence here establishes those answers.
A smaller amount doesn’t automatically become a known safe amount either. The missing studies leave both benefit and harm uncertain. There’s no FDA-approved KLOW dosing label to fill that gap.
Compounded medicines are not FDA-approved. FDA’s explanation of compounding helps separate the prescription process from approval of a product.
Questions for a clinical conversation
What exact substances are being considered? What evidence fits the condition and proposed route? What approved treatments address the same problem? These questions keep the conversation about the person’s care, rather than about reproducing a research method.
It’s also reasonable to ask what uncertainty would lead the clinician to decline, and how safety concerns would be handled. An assessment can end with another option or no peptide prescription.
The safety page covers the main unanswered risks. The ingredient introduction explains why the four names need to stay distinct.